ArticleCells2026
Cell Death Induction by MO2455, a Novel Potential Anti-Cancer Agent in Monocytic and T-Cell Leukemia Cells.
Ankitha Vadi Velu, Kenji Matsuno, Barkha Saraswat, Osamu Ohno, Yu Yingchun, Zhao Zhenkai, Ying Tong, Takahiro Tougan, Taiki Aoshi, Takeji Takamura and 2 more
Abstract read
In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Ankitha Vadi VeluDepartment of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0003-4136-6909 Kenji MatsunoDepartment of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan.
Barkha SaraswatDepartment of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0009-0005-4579-8348 Osamu OhnoDepartment of Chemistry and Life Science, School of Advanced Engineering, Kogakuin University, Tokyo 192-0015, Japan.ORCID 0000-0002-8147-6857 Yu YingchunDepartment of Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Zhao ZhenkaiDepartment of Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Ying TongDepartment of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0009-0004-9476-8359 Takahiro TouganDepartment of Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Taiki AoshiDepartment of Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Fumiaki KoizumiDepartment of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Mitsuko MasutaniDepartment of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.ORCID 0000-0003-2631-4334 Funding
Japan Agency for Medical Research and Development 15Ack0106021, 17ck0106286Ministry of Education, Culture, Sports, Science and Technology KibanB 22300343, H23-Jitsuyoka (Gan)-004
6 · The paper itselfAbstract
Despite advances in targeted therapies, treatment resistance and disease recurrence remain major obstacles in leukemia management. Structural modification of clinically successful kinase inhibitors represents a promising approach for discovering novel anti-leukemic agents with improved biological activities. In the present study, we investigated the anti-leukemic activity and mechanism of action of MO2455, a newly synthesized imatinib-derived compound, in monocytic leukemia U937, THP-1, and T-cell leukemia CCRF-CEM cells. MO2455 showed substantial cytotoxic activity against all three cell lines, with IC
Indexed as
Antineoplastic AgentsImatinib MesylateLeukemia, T-CellApoptosisApoptosis Regulatory ProteinsCell DeathCell Line, TumorDNA FragmentationHistonesHumansMembrane Potential, MitochondrialMonocytesProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2U937 CellsAntineoplastic AgentsApoptosis Regulatory ProteinsBBC3 protein, humanHistonesImatinib MesylateProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2apoptosiscell deathDNA damageimatinib derivativeleukemiamitochondrial dysfunction
Identifiers
PMID42882478
PMCPMC13664501
What OpenQuestion holds
Textmetadata
Read underepoch 390